In a substudy of the AMAZES trial, azithromycin, when used as a treatment for exacerbations in patients with severe asthma, reduced Haemophilus influenzae load but also increased resistance to antibiotics, researchers reported in the American Journal of Respiratory and Critical Care Medicine.
